ViiV Healthcare Reports P-III (LATITUDE) Trial of Cabenuva in Adherence-Challenged HIV Patients
ViiV Healthcare presented results from the Phase III LATITUDE trial evaluating Cabenuva, a long‑acting injectable of cabotegravir and rilpivirine, in 453 adults with adherence challenges. Among 306 virally suppressed participants, the quarterly injection reduced cumulative regimen failure to 22.8% versus 41.2% for daily oral ART over 48 weeks. Virologic failure rates were 6.8% versus 28.2%, and treatment discontinuations were lower in the injectable arm. The data, published in NEJM, support further investigation in the CROWN study for patients with detectable virus.
Radiopharmaceutical Therapy Use Has Increased 2,000% Among Medicare Population
Radiopharmaceutical therapy (RPT) utilization among Medicare beneficiaries surged 2,000% between 2013 and 2023, climbing from 529 to 12,395 IV administrations. The study identified a 37% compound annual growth rate, with diagnostic and interventional radiology delivering 45.2% of services and nuclear...
High Risk Research: HHS Should Publicly Share More Information on How Risk Is Assessed and Mitigated
The Government Accountability Office (GAO) reports that the Department of Health and Human Services (HHS) conducts risk assessments for gain‑of‑function research but does not consistently share those findings with the public. While the research has expanded understanding of pathogen transmission,...
Roland DGA Launches Elevate Denture Solution for Digital Workflows
Roland DGA has introduced the Elevate Denture Solution, a digital denture kit that bundles Ivoclar Ivotion discs, hyperDENT CAM strategies, adapters and PMMA tooling for use with DGSHAPE DWX‑53 series mills. Developed with Ivoclar and FOLLOW‑ME! Technology, the solution offers...
Private Health Insurance: Provider Participation and Payments for Selected Services Before and After the No Surprises Act
The Government Accountability Office examined how the No Surprises Act affected provider participation and payment levels for emergency medicine, radiology, anesthesiology and air‑ambulance services from 2019 through 2023. After the act’s protections took effect on January 1 2022, the share of in‑network...
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
CRISPR Therapeutics shares rose over 12% after reporting Q4 2025 earnings that showed a larger‑than‑expected loss and minimal recognized revenue. The company’s flagship therapy CASGEVY generated $54 million in sales, but under its revenue‑sharing deal with Vertex only $0.86 million was recorded. CRISPR...
STAT+: What to Expect From Gossamer Bio’s Late-Stage Lung Disease Study
Gossamer Bio is set to announce results from its Phase 3 trial in pulmonary arterial hypertension (PAH) before the end of February. The readout follows a Phase 2 study that delivered modest, sub‑par efficacy, which the company attributes to an...
DHL Expands Airfreight Cold Chain Network
DHL Group is expanding its dedicated air‑freight cold‑chain network, adding more than 30 GDP‑compliant aviation hubs and a new Brussels‑Cincinnati corridor. The rollout is part of a €2 bn investment in DHL Health Logistics and includes a dedicated Boeing 777 freighter painted...
Anthropic: It’s “Critical” To Bring Company Products to EHR
Anthropic is pushing its Claude AI model into electronic health record (EHR) systems, arguing that integration is essential for real‑time clinical value. The company highlighted a roster of 25 healthcare partners, including Abridge, Novo Nordisk, Genmab and Banner Health, to showcase both...
Prevention Is Turning a Corner as Public Demand Surges – but NHS Digital Infrastructure Is Still Lagging Behind
Public demand for preventative health in the UK is surging, with NHS App registrations now at 33.6 million – roughly twice the nation’s Netflix subscriber base. A PA Consulting survey shows eight‑in‑ten NHS leaders believe digital tools can cut health inequalities,...
Nevada Debuts Public Option Amid Tumultuous Federal Changes to Health Care
Nevada launched its Battle Born public option health plans last fall, aiming to lower premiums and expand coverage. Early enrollment reached just over 10,000 members, far short of the 35,000 target set by state officials. The program must cut premiums...
MSD and Mayo Clinic Team up to Advance AI in Drug Development
Merck (MSD) and Mayo Clinic have launched a research partnership that blends Mayo's Platform architecture and multimodal clinical‑genomic data with MSD's virtual‑cell technologies. The collaboration gives MSD direct access to de‑identified imaging, lab, molecular and notes data to train and...
Alira Health Sued for Stock Manipulation and Fraud
Alira Health and its CEO Gabriele Brambilla face multiple lawsuits from startup founders alleging fraud, unjust enrichment, and violations of the Securities Exchange Act. The plaintiffs claim Alira used inflated stock to acquire companies, set unattainable performance targets, and then...
Opinion: My Biggest GLP-1 Ethical Problem: Patients Who Don’t Want to Stop
GLP‑1 agonists have moved from scarcity to abundance, reshaping weight‑management practice. In 2023, shortages forced clinicians to ration these drugs, often off‑label for obesity. Today, the surplus creates a new dilemma: patients seeking extreme, unsustainable weight loss and refusing to...
Verily Launches Self-Serve Access to Pre Platform with New Segmed and RefinedScience Datasets
Alphabet’s Verily has introduced a free, self‑serve Standard tier for its Pre precision‑health platform, allowing researchers to access the Exchange catalog and Workbench environment with just a Google account. The rollout adds three high‑impact datasets: a single‑cell AML cohort from...
Stratasys Introduces Multi-Material 3D Printed Anatomical Model Preset for Dental Training
Stratasys has launched a multi‑material 3D‑printed dental anatomical model preset using its PolyJet technology, enabling realistic, customizable training devices. The preset defines material ratios and distribution patterns to consistently mimic bone, teeth, nerves, and soft tissue. Models can be personalized...
Gold@MnFe‐Prussian Blue Analog Yolk@Shell Nanoparticles for Light‐Triggered and pH‐Sensitive Drug Release
Researchers have engineered Au@MnFe‑Prussian Blue Analog yolk‑shell nanoparticles that combine a hollow cavity with a functional shell for biomedical use. The synthesis creates a ~75 nm interior, achieving roughly 50% loading efficiency for the chemotherapeutic doxorubicin. Partial etching and redeposition of...
Achieving High‐Efficiency Type I Multimodal Photosensitizers via a Synergistic Rigidity‐Flexibility Strategy for Hypoxia‐Resistant Tumor Therapy
Researchers introduced a donor‑acceptor (D‑A) molecular design that couples a rigid coplanar backbone with flexible side chains, dramatically raising near‑infrared molar extinction and fluorescence brightness. The resulting phenothiazine‑based photosensitizer, EL‑TPO2F, also exhibits strong type‑I reactive oxygen species (ROS) production and...
Swedish CubaseBio Emerges From Stealth with €5.9 Million to Scale Volumetric DNA Microscopy
Swedish startup CubaseBio has emerged from stealth after raising €5.9 million in blended financing – a €2 million European Innovation Council grant plus €3.9 million from Voima Ventures, Nordic Science Investments, Illumina Ventures and other life‑science investors. The capital will accelerate development of...
Hampshire Hospitals NHS Foundation Trust Boosts Imaging Productivity and Resilience Following Major CT Upgrade
Hampshire Hospitals NHS Foundation Trust has completed a major CT upgrade, standardising imaging across Basingstoke, Winchester and Andover with a unified fleet of Canon Aquilion ONE/PRISM and Aquilion Prime SP scanners. The project introduced a dedicated cold‑site CT in Basingstoke,...
9 Companies Hiring Now in Pennsylvania
Pennsylvania’s Greater Philadelphia corridor remains a biotech hotbed, housing over 1,200 life‑science firms including AstraZeneca, GSK and Johnson & Johnson. Eli Lilly announced a new injectable weight‑loss manufacturing plant in the Lehigh Valley, projected to create roughly 850 jobs by 2031....
Lancashire and South Cumbria NHS Chooses EBO’s Patient Portal
Lancashire and South Cumbria NHS Foundation Trust is rolling out EBO’s Intelligent Patient Portal (IPP) as part of its digital transformation, offering a conversational AI interface that guides patients through appointment management and care tasks. The portal is built on...
NHS Transformation Directorate Launches Best Practice and Content Guidance for Patient Messaging
The NHS Transformation Directorate has issued best‑practice and content guidance to help NHS staff decide when and how to message patients via NHS Notify, the NHS App, text, email or letters. The guidance combines clinical safety, governance and digital best...
Elsevier ClinicalKey AI Adds NEJM, The Lancet, and HIPAA Compliance
Elsevier has upgraded its ClinicalKey AI platform by adding full‑text access to more than 130 top‑tier medical journals, including NEJM and The Lancet, and by integrating clinical guidelines from leading societies. The new version introduces real‑time traceability, linking AI‑generated answers...
Big Food Pours Millions Into Rebrands as Obesity Drugs Reshape US Demand
US food and beverage giants are accelerating rebranding and product reformulation as GLP‑1 obesity drugs reshape consumer demand. Appetite‑suppressing medications are projected to erase up to $12 billion in snack sales over the next decade, prompting companies like PepsiCo, Coca‑Cola and...
Master Bond Debuts UV26DCMed Dual-Cure Adhesive
Master Bond introduced UV26DCMed, a single‑component, dual‑cure adhesive for medical device assembly that combines UV light for rapid fixturing with a heat bake for full polymerization. The formulation tolerates repeated sterilization methods—including steam autoclave, ethylene oxide, glutaraldehyde, and hydrogen‑peroxide—while meeting...
Scientists Develop the World’s Tiniest Wireless Brain Implant
Scientists at Cornell University have created a wireless brain implant so small it can sit on a grain of salt, yet still record and transmit neural activity. The device uses light‑based optics for power and data, eliminating bulky wires and...
Nib Appoints Soccer Star Mary Fowler As Chief Health & Wellbeing Officer
Nib Group has appointed Australian soccer star Mary Fowler as its chief health and wellbeing officer, underscoring the insurer's push for health literacy, inclusion and female representation. Fowler will leverage her athletic platform to inspire Australians to prioritize wellness and...
Bone Marrow Cell Atlas Created for Improved Leukemia Research
Researchers at the Princess Máxima Center have produced the first multimodal single‑cell atlas of healthy pediatric bone marrow, profiling nearly 91,000 cells from nine donors aged two to 32. The atlas reveals that children’s marrow differs markedly from adult marrow in...
How Pennant, LiveWell, Grow With A Density-First Mindset
Home‑based care providers are shifting from a broad geographic footprint to an operational‑density model, making clustered agencies the cornerstone of growth. LiveWell Partners emphasizes expanding density within states it already serves, exemplified by its recent acquisition of Empower Home Health...
Cancer Immunotherapy Improved Using Targeted Stress Protein
Researchers at NYU Langone Health identified the integrated stress response protein lipocalin 2 (LCN2) as a key mediator that lets lung and pancreatic tumors evade immune attack. In mouse models, antibodies that block LCN2 restored T‑cell infiltration, slowed tumor growth, and...
Dr. Hope Jacoby, Podiatrist: Leading with Precision in Podiatry
Dr. Hope Jacoby, DPM, has built a leading podiatric practice in Dallas‑Fort Worth, focusing on advanced wound care and foot‑ankle surgery. Her career stems from a sports‑focused upbringing, elite athletic training, and a chief residency that honed surgical leadership. She...
Grail Inc (GRAL) Q4 2025 Earnings Call Transcript
Grail reported Q4 2025 revenue of $36.2 million, a 26% year‑over‑year rise, driven by 45,000 Gallery tests sold—a 39% volume increase. The company completed a $325 million private placement, boosting cash to roughly $850 million, and announced a strategic partnership with Samsung that...
Pulse Biosciences Inc (PLSE) Q4 2025 Earnings Call Transcript
Pulse Biosciences reported its first commercial revenue of $86,000 from limited market release of the nPulse platform and Vibrance disposables. The company completed over 200 procedures across pilot programs and advanced multiple clinical studies, including FDA IDE clearance for the...
Host Control of Persistent Epstein–Barr Virus Infection
A multinational consortium investigated how host genetics influence persistent Epstein‑Barr virus (EBV) infection. Using large‑scale genome‑wide association studies across diverse cohorts, the team identified several host loci that modulate viral load and serostatus. Functional analyses linked these loci to immune...
Blood Test Holds Promise for Predicting when Alzheimer’s Symptoms Will Start
Researchers have developed a blood test that quantifies an abnormal form of tau protein, acting as a molecular clock to predict not only the likelihood of Alzheimer’s disease but also the timing of symptom onset. The study, published in Nature...
AMN Healthcare Services Inc (AMN) Q4 2025 Earnings Call Transcript
AMN Healthcare reported Q2 2025 revenue of $658 million, hitting the top of its guidance but falling 11% year‑over‑year. A $110 million goodwill impairment drove a GAAP net loss of $116 million, while adjusted EBITDA slipped to $58 million with an 8.9% margin. Gross...
Guardant Health Inc (GH) Q4 2025 Earnings Call Transcript
GE HealthCare reported Q4 2025 revenue of $5.7 billion, up 4.8% organically, and posted a record backlog of $21.8 billion with a book‑to‑bill ratio of 1.06. Adjusted EBIT margin slipped to 16.7% after a $100 million tariff hit, while adjusted EPS fell 0.7%...
Travere Therapeutics Inc (TVTX) Q4 2025 Earnings Call Transcript
Vertex Pharmaceuticals reported fourth‑quarter 2025 revenue of $3.2 billion, a 10% year‑over‑year increase, and full‑year revenue of $12 billion, up 9%. The company highlighted strong growth in its cystic fibrosis (CF) franchise, with 7% global expansion and double‑digit gains in the...
Pharmacogenomics of Antiepileptic Drug Mood Stabilizer Treatment Response in Bipolar Disorder: A MoStGen Consortium Study
The Mood Stabilizer Genomics (MoStGen) Consortium analyzed 917 bipolar disorder patients to identify genetic predictors of response to antiepileptic mood stabilizers (AMS). Genome‑wide association studies revealed a robust association between lamotrigine response and variants in ROBO2, and a gene‑level signal...
Inseego Corp (INSG) Q4 2025 Earnings Call Transcript
Inspire Medical Systems reported fourth‑quarter revenue of $269 million, a 12% increase, and full‑year revenue of $912 million, up 14% year‑over‑year, driven by existing and new center growth. The company set 2026 revenue guidance between $950 million and $1 billion, reflecting a 4%‑10% growth...
A Transcriptional Program Associated with Neurotransmission in the Living Human Brain
Researchers from the Living Brain Project combined prefrontal cortex biopsies from 130 neurosurgical patients with intracranial recordings of dopamine, serotonin, and other neurotransmitters. Differential‑expression analyses of single‑nucleus and bulk RNA‑seq data revealed reproducible gene‑expression signatures that correlate with fast‑scan cyclic...
Weave Communications Inc (WEAV) Q4 2025 Earnings Call Transcript
Weave Communications reported Q2 2025 revenue of $58.5 million, a 15.6% year‑over‑year increase, and beat the top end of its non‑GAAP guidance. Gross margin rose to 72.3%, up 40 basis points, while free cash flow reached $4.5 million and cash balances stood...
Exercise Mimetics as Unexplored Therapeutics for Treating Depression
The paper proposes exercise mimetics—pharmacological agents that imitate endurance training—as a novel class of antidepressants. While regular physical activity cuts depression risk by about 18 percent, adherence challenges limit its real‑world impact. Exercise mimetics activate muscle signaling pathways and alter the...
Tandem Diabetes Care Inc (TNDM) Q4 2025 Earnings Call Transcript
Tandem Diabetes Care reported record 2020 results, generating roughly $500 million in revenue—a 38% year‑over‑year increase—and shipping more than 90,000 insulin pumps. The company now serves over 200,000 customers worldwide and has expanded its Control‑IQ automated insulin‑delivery algorithm, which has driven...
Select Medical Holdings Corp (SEM) Q4 2025 Earnings Call Transcript
Select Medical disclosed that its Board is evaluating a non‑binding take‑private proposal from the Executive Chairman, adding strategic uncertainty to the near‑term outlook. Fourth‑quarter revenue grew more than 6% year‑over‑year, but adjusted EBITDA dropped 10% to $104.7 million, driven by an...
ICU Medical Inc (ICUI) Q4 2025 Earnings Call Transcript
ICU Medical reported Q3 2025 revenue of $533 million, a 5% organic increase, driven by record consumables sales and solid IV systems growth. Adjusted diluted EPS rose 28% to $2.30 and adjusted EBITDA reached $106 million, reflecting higher gross margins and lower...
Insmed Inc (INSM) Q4 2025 Earnings Call Transcript
Insmed reported a $144.6 million net revenue for Brinsupri’s first full U.S. quarter, surpassing internal launch benchmarks. Management set a minimum $1 billion Brinsupri revenue target for 2026 and projected total company revenue to more than double 2025 levels, driven by continued...
Materialise NV (MTLS) Q4 2025 Earnings Call Transcript
Materialise posted a mixed third‑quarter 2025 performance, with overall revenue slipping 3.5% year‑over‑year but the Medical segment hitting a record €33.3 million, up more than 10%. Software and Manufacturing revenues fell 7% and 17% amid macro‑economic headwinds, while operating cash flow...
Madrigal Pharmaceuticals Inc (MDGL) Q4 2025 Earnings Call Transcript
Gilead Sciences reported total product sales of $28.9 billion for 2025, a 1% increase that topped the high end of its guidance. The HIV franchise generated $20.8 billion, up 6% overall and 10% on an underlying basis after removing the Medicare Part D...